Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Wnt/β-catenin–activated Ewing sarcoma cells promote the angiogenic switch
Allegra G. Hawkins, … , Rashmi Chugh, Elizabeth R. Lawlor
Allegra G. Hawkins, … , Rashmi Chugh, Elizabeth R. Lawlor
Published June 16, 2020
Citation Information: JCI Insight. 2020;5(13):e135188. https://doi.org/10.1172/jci.insight.135188.
View: Text | PDF
Research Article Cell biology Oncology

Wnt/β-catenin–activated Ewing sarcoma cells promote the angiogenic switch

  • Text
  • PDF
Abstract

Wnt/β-catenin signaling is active in small subpopulations of Ewing sarcoma cells, and these cells display a more metastatic phenotype, in part due to antagonism of EWS-FLI1–dependent transcriptional activity. Importantly, these β-catenin–activated Ewing sarcoma cells also alter secretion of extracellular matrix (ECM) proteins. We thus hypothesized that, in addition to cell-autonomous mechanisms, Wnt/β-catenin–active tumor cells might contribute to disease progression by altering the tumor microenvironment (TME). Analysis of transcriptomic data from primary patient biopsies and from β-catenin–active versus –nonactive tumor cells identified angiogenic switch genes as being highly and reproducibly upregulated in the context of β-catenin activation. In addition, in silico and in vitro analyses, along with chorioallantoic membrane assays, demonstrated that β-catenin–activated Ewing cells secreted factors that promote angiogenesis. In particular, activation of canonical Wnt signaling leads Ewing sarcoma cells to upregulate expression and secretion of proangiogenic ECM proteins, collectively termed the angiomatrix. Significantly, our data show that induction of the angiomatrix by Wnt-responsive tumor cells is indirect and is mediated by TGF-β. Mechanistically, Wnt/β-catenin signaling antagonizes EWS-FLI1–dependent repression of TGF-β receptor type 2, thereby sensitizing tumor cells to TGF-β ligands. Together, these findings suggest that Wnt/β-catenin–active tumor cells can contribute to Ewing sarcoma progression by promoting angiogenesis in the local TME.

Authors

Allegra G. Hawkins, Elisabeth A. Pedersen, Sydney Treichel, Kelsey Temprine, Colin Sperring, Jay A. Read, Brian Magnuson, Rashmi Chugh, Elizabeth R. Lawlor

×

Figure 3

β-Catenin–activated Ewing cells secrete factors that promote HUVEC proliferation.

Options: View larger image (or click on image) Download as PowerPoint
β-Catenin–activated Ewing cells secrete factors that promote HUVEC proli...
(A) Expression of β-catenin target genes in A673 and CHLA10 cells following stable transduction with empty vector or constitutively active β-catenin (EBP). Levels were determined by quantitative real-time PCR (qRT-PCR) in each sample, and expression was normalized to housekeeping genes. Data shown are fold change relative to empty vector for 3 independent biologic replicates. (B) CM from A673 and CHLA10 cells containing either empty or EBP vector was collected and added to HUVECs. Proliferation (C) and viability (D) of HUVECs were measured 1, 3, and 5 days following addition of Ewing CM. P values were computed using 2-tailed t tests (A–D). *P < 0.05, **P < 0.01, n ≥ 3 independent experiments (A–D).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts